Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

Abstract

For patients with secondary loss of efficacy from infliximab or etanercept, switching to adalimumab can restore a good clinical response.